HomeAI · summaries
Storia in 4 fonti
AstraZeneca's triplet combo succeeds in some liver cancer patients
AstraZeneca on Monday reported data from a new combination study showing a combination of targeted and immunotherapies can benefit patients with certain kinds of liver cancer.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a broader FDA label in metastatic castration-resistant…
- ·
healio.com
Immunotherapy combination may improve outcomes in unresectable liver cancer
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to…
- ·
endpoints.news
AstraZeneca's triplet combo succeeds in some liver cancer patients
AstraZeneca on Monday reported data from a new combination study showing a combination of targeted and immunotherapies can benefit patients with certain kinds of liver cancer.
- ·
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing…
- ·
benzinga.com
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial - AstraZeneca (NYSE:AZN)
AstraZeneca's EMERALD-3 trial shows improved progression-free survival with STRIDE, lenvatinib and TACE in liver cancer.